Metabolic abnormalities in patients with HIV infection;Anormalidades metabólicas en pacientes con infección por VIH

Revista de Investigacion Clinica

Volumn 56, Issue 2, 2004, Pages 193-208

  Rodríguez Carranza, Sandra I ^a   Aguilar Salinas, Carlos A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiretrovirals; Dyslipidemias; Human immunodeficiency virus; Lipodistrophy; Protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CD4 ANTIGEN; EFAVIRENZ; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; STAVUDINE; SULFONYLUREA DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ABDOMEN; ABDOMINAL DISTENSION; ANOREXIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSLIPIDEMIA; ETHNIC GROUP; FACE; FATIGUE; HEALTH PRACTITIONER; HEART DISEASE; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIMB; LIPID BLOOD LEVEL; LIPID STORAGE; LIPODYSTROPHY; LIVER DYSFUNCTION; LONGITUDINAL STUDY; MEDICAL SPECIALIST; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MORBIDITY; MORTALITY; MULTIFACTORIAL INHERITANCE; NAUSEA; NECK; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATHOPHYSIOLOGY; REVIEW; SUBCUTANEOUS FAT; VOMITING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC DISEASES;

EID: 4243130588     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient study investigators. N Engl J Med 1998; 338: 853-60.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
3. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Research 2001; 51(3): 151-77.
4. Klein D. Do protease inhibitors increase the risk for coronary disease among HIV positive patients-follow up. 2001, 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA.
5. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106(11): 1420-7.
6. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5: 329-33.
7. Mary-Krause M. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. 2001, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. USA.
8. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25(7): 1253-4.
9. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348(8): 702-10.
10. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS and the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-8.
11. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958-60.
12. Head G, Mehta NJ, Khan IA, Mehta RN, Gowda RM. Acute coronary syndrome in patients with human immunodeficiency virus disease. Angiology 2002; 53: 545-9.
13. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J M 2003; 348(8): 679-80.
14. Hadigan C, Meigs JB, Rabe J, D, Agostino RB, Wilson PWF, Lipinska I, Tofler GH. Grinsspoon S. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86(2): 939-43.
15. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002; 87(10): 4611-15.
16. Dressman J, Kincer J, Matveev S, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003; 111: 389-97.
17. Green ML. Evaluation and management of dyslipidemia in patients with HIV infection. JGIM 2002; 17: 797-810.
18. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994; 7: 1149-56.
19. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV Disease. Curr Opin Lipidol 2001; 12: 313-19.
20. Riddler S, Smit E, Cole S at al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-82.
21. Friis-Moller N, Weber R, Reiss P. et al. Cardiovascular disease risk factors in HIV patients- association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-93.
22. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999, 33: 859-63.
23. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-9.
24. Pujol RM, Domingo P, Xavier Matias G, Francia E. Sanbeat MA, Alomar A. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol 2000; 42: 193-8.
25. Panse I, Vasseur E, Raffin-Sanson ML, Staroz R, Rouveix E, Saiag P. Lipodystrophy associated with protease inhibitors. Br J Dermatol 2000; 142: 496-500.
26. Behrens G, Dejam A, Schimidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schimidt RE, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-70.
27. Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated with increased risk of cardiovascular disease is associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS 2000; 11: 451-5.
28. Garcia-Benayas T, Blanco F, de la Cruz JJ, Senchordi MJ, Gomez-Viera JM, Soriano V, Gonzalez-Lahoz J. Role of nonnucleosides in the development of HAART-related lipid disturbances. J Acquir Immune Defic Syndr 2001; 28: 496-8.
29. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs and role of hypolipidaemic therapy with bezafibrate. J Infect 2001; 42: 181-8.
30. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160: 3050-6.
31. Periard D, Talenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-5.
32. Roge BT, Katzenstein TL, Gerstof J. Comparison of P-trygliceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scand J Infect Dis 2001; 33: 306-11.
33. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA. PIILR Study Group. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811-22.
34. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Valentin VD. Serum triglycerides. HIV infection, and highly active antiretroviral therapy. Aquitaine Cohort. France 1996 to 1998. Groupe Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000; 23: 261-5.
35. Vergis EN, Paterson DL. Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001; 12: 463-8.
36. Currier J. Management of metabolic complications of therapy. AIDS 2002; 16 (Suppl 4): S171-S176.
37. Badaro R, DeJesus E, Lazzarin A, Jemsek J, Clotet B, Rightmire A, Thiry A, Wilber R. Atazanavir with ritonavir or saquinavir vs. lopinavir/ritonavir in patients with multiple virologic failures. Memories of 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV,July 8-11, Paris, France.
38. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy:preliminary results of LIPOCO study. AIDS 2000; 14: 37-49.
39. Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1 infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29: 21-31.
40. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1 infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001; 27: 443-9.
41. Martinez E, García-Viejo M, Blanco JL, Bianchi L, Buira E, Conget I. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in succesfully treated adults with lipodystrophy. Clin Infect Dis 2000; 31: 1266-73.
42. Casado JL, Arrizabalaga J, Antela A. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: a 52 week, multicenter, prospective study. Eight Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 (abstract 673).
43. Van der Valk M, Kastelein J, Murphy R, Van Leth F, Katlama C, Horban A. Nevirapine-containing antiretroviral therapy in HIV-1 infected patient results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14.
44. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects Ander long-term succesful triple combination therapy. AIDS 2000; 14: 807-12.
45. Kosmiski LA, Kuritzkes DR, Lichteinstein KA, Glueck DH, Gourley PJ, Stamm ER. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15: 1993-2000.
46. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N. Metabolic abnormalities and cardiovascular risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9.
47. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465-71.
48. Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, Tashima KT, Carpenter CC. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999; 21: 107-13.
49. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM. Effect of ritonavir on lipids and postheparine lipase activities in normal subjects. AIDS 2000; 14: 51-7.
50. Petit JM, Doung M, Florentin E, Duvillard L, Chavanet P, Brun JM, Portier H, Gambert P, Verges B. Increased VLDL-apolipoprotein B and IDL-apolipoprotein B production rates in non lipodystrophic HIV-infected patients on a protease inhibitor containing regimen. A stable isotope kinetic study. J Lipid Res 2003 (in press).
51. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7: 1327-31.
52. Grunfeld C, Doerrier W, Pang M, Jensen P, Weisgraber KH, Feingold KR. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997; 82: 3734-40.
53. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A, Massip P, Chap H, Perret B. An interaction between apoc C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15: 2397-406.
54. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol Endocrinol Metab 2001; 280: E549-E553.
55. Noor M, Lo JC, Mulligan K, Halvorsen R, Schwarz J, Shambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative subjects. Antiviral Therapy 2000; 5-8.
56. Noor MA, Senerivatne T, Aweeka FT. The HIV protease inhibitor indinavir acutely inhibits insulin-stimulated glucose disposal: a randomized, placebo-controlled study. Antiviral Therapy 2001; 6: 4.
57. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 2001; 12(9): 413-9.
58. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1467-75.
59. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-4.
60. Leow MKS, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003; 88(5): 1961-76.
61. Addy CI, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocr Metab 2003; 88(2): 627-36.
62. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Jarvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88(4): 1907-10.
63. Tong Q, Sankalé JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK and Hotamisligil S. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocr Metab 2003; 88(4): 1559-64.
64. Van Gaal LF, Mertens IL, Abrams PJ. Health risks of lipodystrophy and abdominal fat acumulation: therapeutic possibilities with leptin and human growth hormone. Growth Horm IGF Res 2003; 13 Suppl: S4-9.
65. Behrens G, Boerner AR, Weber K, Van den Hoff J, Ockenga J, Brabant G, Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance cin HIV-1 infected patients with lipodystrophy. J Clin Invest 2002; 110(9): 1319-27.
66. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM. Hyperinsulinemia, hyperglycemia and impaired hemostasis: The Framingham Offspring Study. JAMA 2000; 283: 221-8.
67. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257.
68. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypert 2003; 21(7): 1377-82.
69. Behrens G, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17 (Suppl. 1): S149-54.
70. Chen D, Misra A, Abhimanyu G. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87(11): 4845-56.
71. HIV lipodystrophy case definition study group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361(9359): 726-35.
72. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J AIDS 2003; 33: 571-6.
73. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
74. Chow DC, Day LJ, Shikuma CM. Metabolic complications of HIV therapy. HIV in Site Knowledge Base Chapter 2003.
75. Muurahainen N, Pettit R, Kotler D, Falutz J, Santos G, Kleintop M, Glesby M. Abnormalities in HIV-associated lipodystrophy syndrome that vary by weight status (abstract 63). 1st International workshop on adverse drug reactions and lipodystrophy in HIV, San Diego, CA: 1999, p. 53.
76. Miller JE, Emery S, French M, Baker D, Cooper DA. The Australian prevalence survey of lipodystrophy. The Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000 (abstract 201).
77. Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipolCoNa Study. Arch Intern Med 2002; 162: 2621-8.
78. Hadigan C, Corcoran C, Piecuch S, Rodriguez W, Grinspoon S. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. J Clin Endocrinol Metab 2000; 85(10): 3544-50.
79. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CF45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17: 1753-62.
80. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Op Infect Dis 2002; 15: 23-9.
81. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Op Infect Dis 2002; 15: 9-16.
82. Dube D, Sprecher K, Henry JA, Aberg FJ, Torriani HN, Hodis J, Schouten J, Levin G, Myers R, Zackin T, Nevin JS, Currier. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the adult ACTG cardiovascular disease focus group. Clin Infect Dis 2000; 31: 1467-75.
83. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003; 17(Suppl 1): S162-9.
84. Yoon C, Gulick R, Hoover D, Vaamonde C, Glesby M. Case-control study of diabetes mellitus in HIV-infected patients. Ninth conference on retroviruses and oportunistic infections. Seattle, 2002.
85. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities. (letter). Lancet 1998; 352: 1031-2.
86. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001; 15: 1503-8.
87. Negredo R, Paredes A, Bonjoch A, Tuldra CR, Fumanz S, Gel B. Benefit to switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow up. Antiviral Ther 1999; 4: 23-38.
88. Martinez I, Conget L, Lozano L, Casanmitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-10.
89. Moyle GJ, Baldwin C, Comitis S, Dent N and Gazzard BG. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz. Antiviral Ther 1999; 4: 48.
90. Walli R, Michi GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6: 413-21.
91. Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV: additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91: 25S-30S.
92. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J.
93. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-9.
94. Aberg JA, Evans AZR. A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipids abnormalities: ACTG 5087. Twelfth International AIDS Conference. Barcelona, 2002: Abstract LbPE B90181.
95. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284(4): 472-7.
96. Gelaton MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, Brebbia JS, Wax FR, McNurlan MA. Improved insulin sensitivity and body fat distribution in HIV infected patients treated with roziglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31(2): 163-70.
97. Walli R, Michl GM, Muhlbayer D, Brinkmann L, Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000; 199(5): 253-62.
98. Rietschel P, Hadigan C, Corcoran T, Stanley G, Neubauer G, Gertner J, Grinspoon S. Assesment of growth hormone dynamics in human inmunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504-10.
99. Johannsson G, Marin P, Lonn L, Ottonson M, Stenlof K, Bjortorp P. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 83: 727-34.
100. Lo JC, Mulligan K, Noor MA, Schwarz J-M, Halvorsen RA, Grunfeld C. The effects of recombinant human gowth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86: 3480-7.